Skip to main content

Table 3 Questionnaire results

From: Patient-reported outcomes following primary total hip arthroplasty in Crowe type III or IV developmental dysplasia are comparable to those in Crowe type I: a case-control study of 96 hips with intermediate-term follow-up

 

H group (23 cases)

Control (46 cases)

P-value

FO group (10 cases)

N-FO group (12 cases)

P-value

Q1. The reason for receiving THA

 1. Hip pain

19

41

0.468

7

11

0.293

 2. Other pain

9

14

0.470

6

3

0.192

 3. Walking disorder

18

40

0.487

8

9

1.000

 4. LLD

13

9

0.002

5

8

0.666

 5. Limits on ROM at hip joint

16

27

0.380

7

8

1.000

Q2. Primary complaint

 1. Hip pain

15

32

0.715

6

8

0.546

 2. Other pain

0

3

0.546

0

0

–

 3. Walking disorder

6

5

0.161

4

2

0.348

 4. LLD

1

0

0.333

0

1

0.545

 5. Limits on ROM at hip joint

1

6

0.411

0

1

0.545

Q3. Satisfaction following THA

 Points

90.3 ± 11.3

91.5 ± 12.5

0.680

84.8 ± 13.2

94.0 ± 6.6

0.057

 Rates, % (n/N)

95.6 (22/23)

93.5 (43/46)

0.593

90.0 (9/10)

100.0 (12/12)

0.455

Q4. Benefits of THA

 1. Hip pain subsided

19

43

0.211

7

11

0.226

 2. Other pain subsided

6

12

0.071

3

3

0.583

 3. Walking disorder improved

16

38

0.216

6

9

0.652

 4. LLD improved

12

9

0.006

5

7

0.515

 5. ROM improved

12

32

0.157

4

7

0.392

Q5. Best outcome

 1. Hip pain subsided

13

29

0.601

6

7

0.639

 2. Other pain subsided

1

3

0.892

0

1

0.545

 3. Walking disorder improved

6

8

0.527

2

3

0.594

 4. LLD improved

2

0

0.108

1

1

0.714

 5. ROM improved

1

6

0.411

1

0

0.455

Q6. Adverse outcomes

 1. Hip pain worsened

0

1

0.667

0

0

–

 2. Other pain worsened

3

4

0.435

1

2

0.571

 3. Walking disorder worsened

3

4

0.435

2

0

0.195

 4. LLD worsened

0

1

0.667

0

0

–

 5. Limits on ROM worsened

0

3

0.290

0

0

–

 6. None

17

33

0.544

7

10

0.229

Q7. Worst outcome

 1. Hip pain worsened

0

1

0.667

0

0

–

 2. Other pain worsened

3

4

0.435

2

1

0.429

 3. Walking disorder worsened

3

4

0.435

2

0

0.195

 4. LLD worsened

0

1

0.667

0

0

–

 5. Limits on ROM worsened

0

3

0.290

0

0

–

 6. None

17

33

0.544

6

11

0.105

Q8. Social problems after THA

 1. High treatment cost

2

2

0.596

0

2

0.286

 2. Long length of stay

4

2

0.09

2

2

0.632

 3. Serious rehabilitation

10

8

0.02

7

2

0.017

 4. Difficult return to work

0

4

0.293

0

0

–

 5. None

13

32

0.284

3

8

0.099

Q9. Worst social problem after THA

 1. High treatment cost

0

1

0.667

0

0

–

 2. Long length of stay

2

2

0.596

0

2

0.286

 3. Serious rehabilitation

10

7

0.01

7

2

0.017

 4. Difficult return to work

0

4

0.293

0

0

–

 5. None

11

32

0.079

3

8

0.099

Q10. Walking indoors

 1. No cane

20

44

0.202

7

12

0.078

 2. Cane

3

2

0.202

3

0

0.078

 3. A walker

0

0

–

0

0

–

 4. Wheelchair

0

0

–

0

0

–

 5. Not walking

0

0

–

0

0

–

Q11. Walking outdoors

 1. No cane

18

38

0.465

6

11

0.105

 2. Cane

4

8

0.640

3

1

0.226

 3. A walker

1

0

0.333

1

0

0.455

 4. Wheelchair

0

0

–

0

0

–

 5. Not walking

0

0

–

0

0

–

Q12. VAS score (mm)

14.2 ± 12.9

9.3 ± 7.5

0.036

23.1 ± 14.4

6.2 ± 8.0

0.001

Q13. THA was still the best choice?

 1. Yes

20

39

0.559

8

11

0.571

 2. Not sure

3

5

0.538

2

1

0.571

 3. No

0

2

0.441

0

0

–

  1. Values are expressed as means ± SD, numbers (n), or percentages (n/N). P-values in bold indicate statistical significance (P < 0.05)
  2. H group high hip dislocation group, FO group femoral shortening osteotomy group, N-FO group non-femoral shortening osteotomy group, THA total hip arthroplasty, LLD leg length discrepancy, ROM range of motion, VAS visual analogue scale
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us